Registration Strip Icon for charts Register for streaming realtime charts, analysis tools, and prices.

ALNY Alnylam Pharmaceuticals Inc

-1.16 (-0.77%)
Last Updated: 10:40:41
Delayed by 15 minutes


Draw Mode:

Volume 50,129
Bid Price 148.10
Ask Price 148.38
News -
Day High 149.7713


52 Week Range


Day Low 147.78
Company Name Stock Ticker Symbol Market Type
Alnylam Pharmaceuticals Inc ALNY NASDAQ Common Stock
  Price Change Change Percent Stock Price Last Traded
-1.16 -0.77% 148.245 10:40:41
Open Price Low Price High Price Close Price Prev Close
149.30 147.78 149.7713 149.40
Trades Volume VWAP Dollar Volume Avg Volume 52 Week Range
1,338 50,129 $ 148.70 $ 7,454,349 - 141.975 - 218.88
Last Trade Time Type Quantity Stock Price Currency
10:41:25 1 $ 148.2528 USD

Alnylam Pharmaceuticals (ALNY) Options Flow Summary

Overall Flow


Net Premium


Calls / Puts


Buys / Sells




Sweeps Ratio


Alnylam Pharmaceuticals Inc Financials

Market Cap Shares in Issue Float Revenue Profit/Loss EPS PE Ratio
18.67B 125.95M - 1.83B -440.24M -3.50 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- - - -

more financials information »

Alnylam Pharmaceuticals News

Loading Messages....

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No ALNY Message Board. Create One! See More Posts on ALNY Message Board See More Message Board Posts

Historical ALNY Price Data

Period Open High Low VWAP Avg. Daily Vol Change %
1 Week151.28152.67144.73149.39615,814-3.04-2.01%
1 Month145.21155.49141.975148.61494,8223.042.09%
3 Months156.49161.3092141.975150.07592,374-8.25-5.27%
6 Months163.82199.38141.975162.51701,228-15.58-9.51%
1 Year191.38218.88141.975171.96645,912-43.14-22.54%
3 Years135.25242.97117.58180.36754,58313.009.61%
5 Years67.25242.9765.81157.75714,26281.00120.44%

Alnylam Pharmaceuticals Description

Alnylam Pharmaceuticals is a leader in the study of RNA interference (RNAi) therapeutics. RNAi is a naturally occurring biological pathway within cells for sequence-specific silencing and regulation of gene expression. Alnylam has four drugs on the market: Onpattro for hATTR amyloidosis, Givlaari for acute hepatic porphyria, Oxlumo for primary hyperoxaluria type 1, and Leqvio for hypercholesterolemia. The firm also has 12 clinical programs across the following therapeutic areas: genetic medicines; cardio-metabolic diseases; hepatic infectious diseases, and CNS/ocular diseases. Additionally, up-front fees from research partnerships have boosted Alnylam's cash levels, and the company stands to see additional milestones and royalties from drugs commercialized under collaboration partnerships.

Your Recent History

Delayed Upgrade Clock